ANZCTR search results

This project aims to evaluate the efficacy of a parent-supervised app-based assessment and intervention program for delivery speech pathology services to children with speech sound disorder (SSD) while they are waiting for standard pathology services. The innovation is in using the program with children on a waiting list. It has been found efficacious in previous studies with children already receiving standard speech pathology services. Primary expected outcome is a new effective approach to managing the chronic shortage of speech pathology services in Australia for children with SSD. Significant benefits will be realised through children accessing low cost speech therapy earlier. The study has two secondary aims. First, we will also test the robustness of our automated speech analysis algorithms for assessment of children’s speech, which has the potential to reduce the time/cost burden of manual speech assessment by speech pathologists. Second, we will explore whether videos of upper body (including face and hand movement) provide insights into how motor control of face and hands changes as speech accuracy increases with treatment.

Reduced neck strength is a risk for concussion in some sports. This study will evaluate the effectiveness of a cervical strengthening and stability program against a control group. We hypothesise that the intervention program will significantly increase strength compared to the control group.

This study evaluates the safety and effectiveness of MiSaver, a cell-based product, in patients who have had a heart attack. MiSaver is designed to help improve heart function. Early research suggests it may enhance heart pumping ability with an acceptable safety profile. The study hypothesizes that MiSaver is safe and improves heart function after a heart attack.

This prospective, open-label, multi-centre national randomised controlled trial (RCT) will assess strategies for methotrexate (MTX) dose reduction and discontinuation in children with nonsystemic juvenile idiopathic arthritis (nsJIA) in stable, minimally active disease, defined as clinically inactive disease (CID) or low disease activity (LDA). The primary outcome is disease flare; secondary outcomes include recapture rates, time to recapture, Wallace Criteria, JADAS71, ACR core variables, and patient-reported measures (JAMAR, CHAQ, PROMIS-25, EQ-5D-Y-5L). The trial also incorporates biospecimen collection and data linkages via the A3BC Registry & Biobank, qualitative research, health economic analysis, exploration of lived experiences, and predictive model development. Participation offers patients, families, and clinicians enhanced support and a structured environment to collaboratively assess flares. Findings will inform treatment decisions and improve care pathways for children with JIA.

It is important while trying to understand the effect of vitamins on the ocular surface and their association with dry eye disease, to try first to characterize the most effective chemical forms of vitamins, utilizing the proper methodologies and supplements with randomized controlled clinical studies. This PhD aims to explore the role of vitamin B12 oral consumption on corneal health and dry eye disease. These findings may in the future guide the development of novel treatment strategies for dry eye disease management.

Brief description of the study purpose: This study aim to identify preferences, barriers, and facilitators for engaging in exercise among women who are diagnosed with breast cancer (or undergoing treatment) and are pregnant / within 18 months of giving birth. Who was it for? This study was eligible for a woman aged 18 years and older diagnosed with breast cancer during pregnancy or within 18 months postpartum in the past 5 years. All participants completed the Exercise and Sport Science Australia (ESSA) pre-exercise screening and obtained medical clearance. Study details Participants who enrolled in this study underwent semi-structured interviews to explore their exercise history, preferences, and the barriers and facilitators influencing physical activity during pregnancy, postpartum, and cancer treatment. Participants were then offered an 8-week supervised online exercise program delivered via Microsoft Teams, consisted of both aerobic and resistance training. Baseline assessments included anthropometrics, functional tests (2-minute step test, chair rise, and 30-second push-up), and quality of life using the EORTC QLQ-C30, with follow-up testing completed 3–5 days after the program. The result from this study helped to investigate the feasibility of running an exercise intervention with this population, and how it affects quality of life, strength, and functional physical capacity.

In this randomised, double-blind, placebo-controlled study, 90 women aged 40 to 55 years experiencing menopausal symptoms will be randomly assigned to receive LactoSpore (Heyndrickxia coagulans MTCC 5856) or a matching placebo for 12 weeks. Changes in self-reported menopausal symptoms, quality of life, depression, anxiety, sleep, and fatigue will be assessed over time. Moreover, to examine potential mechanisms of action, changes in sex-related hormones, metabolic-related hormones, an inflammatory marker, and blood lipids will be evaluated.

Study Purpose This study aims to evaluate a new investigational treatment called IMD303 to determine a safe dose and understand how the body responds to it in people with advanced solid cancers. Who Can Participate? You may be eligible for this study if you are aged 18 years or older and have an advanced or recurrent solid tumour such as melanoma, non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, or bladder cancer and whose cancer has progressed despite standard treatment, who cannot tolerate standard treatment, or who have chosen not to pursue further standard therapy. Study details Those who are eligible will receive IMD303 as an intravenous infusion on Day 1 of each treatment cycle. Each dose level will include around 3 to 6 participants, and there is an element of chance because participants are enrolled into sequential dose groups depending on when they join the study. Study Duration The anticipated study duration for each participant in Phase 1a is at least four treatment cycles (each cycle is of 21 days). The Safety Monitoring Committee may assess whether the treatment could continue beyond Cycle 8 based on the emerging evidence of clinical benefit (e.g., partial or complete response). Potential Benefits It is hoped that this research will help determine whether IMD303 is safe and how it affects cancer growth, providing important early information that may support the development of new treatment options in the future.

When someone is undergoing hyperbaric oxygen therapy (HBOT), they are exposed to higher amounts of oxygen than they would normally get every day. It is believed that the heart may respond to more oxygen differently depending on: · Age / Sex · Other medical conditions With this study, we perform an ultrasound scan of the heart before, during, and after your HBOT to see its response. The information we get from these scans may help us better understand patients with different medical conditions react to HBOT and improve how care is provided in hospitals and other HBOT units in Australia.

This pilot study aims to evaluate the acceptability, usability, and feasibility of a custom-made, fully immersive virtual reality (VR) shopping tool designed to train Instrumental Activities of Daily Living. It also aims to explore preliminary effects in functional ability, health-related quality of life, community participation, and implementation outcomes (adoption and appropriateness). Participants will include community-living adults (older adults with mild cognitive impairment, adults with functional vision impairment, adults with acquired brain injury, and healthy older adult controls) and clinicians working with these populations. Participants will complete a four-week VR intervention consisting of two 30-minute sessions per week, with task difficulty tailored and progressively adjusted. Primary outcomes will be assessed using a purpose-designed questionnaire, focus groups, and semi-structured interviews. Secondary outcomes include in-app VR performance metrics, measures of functional ability and quality of life, and community participation in shopping activities. Expected outcomes include evidence of feasibility and preliminary therapeutic potential.